Skip to main content

Table 1 Publications included in data extraction

From: PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials

Publication title

First Author, year

Study acronym

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1

Andre, 2021 [18]

SOLAR-1

Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR +), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial

Juric, 2019 [19]

SOLAR-1

Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Baselga, 2017[15]

BELLE-2

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2

Campone, 2018 [20]

BELLE-2

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cristofanilli, 2016[21]

PALOMA-3

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Turner, 2018 [22]

PALOMA-3

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Di Leo, 2018 [23]

BELLE-3

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer

Dickler, 2018 [24]

 

Phase II trial of temsirolimus in patients with metastatic breast cancer

Fleming, 2012 [25]

 

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2

Hortobagyi, 2016 [26]

BOLERO-2

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Krop, 2016 [27]

FERGI

Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Mayer, 2014 [28]

 

A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-specific Inhibitor, with Letrozole in ER + /HER2-Negative Metastatic Breast Cancer

Mayer, 2017 [29]

 

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR + , HER2- advanced breast cancer: results from BOLERO-2

Moynahan, 2017 [30]

BOLERO-2

Natural history and outcome of patients presenting a metastatic breast cancer (mBC) with PIK3CA mutation

Mosele, 2019 [31]

SAFIR02_Breast

Phase III study of Taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients with ER + , PIK3CA-mutant, locally advanced or metastatic breast cancer: Primary analysis from SANDPIPER

Baselga, 2018 [13]

SANDPIPER

Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant

Tolaney, 2022 [32]

MONARCH 2